adMare Industry Builder series featuring François Ravenelle: The Story Behind Inversago Pharma's Success

The past year has been full of successes for the Canadian life sciences industry. The story of Inversago Pharma is a prime example. The Montreal-based company has developed peripherally acting CB1 receptor (CB1r) blocker therapies designed to help patients with complications associated with metabolic diseases. Last summer, Inversago announced its acquisition by Novo Nordisk, the world leader in the treatment of cardiometabolic diseases, totaling up to US$1.075 billion. A success with positive benefits for the entire life sciences industry! 

On March 28, starting at 12 pm ET, join us for an adMare Industry Builder Series webinar with François Ravenelle, President and CEO of Inversago Pharma. Learn more about the company's journey, from the key decisions to success to the obstacles the team had to overcome and get the CEO's perspective on his experience with Inversago. 

About François Ravenelle

As CEO of Inversago, the leader in the development of next generation CB1 receptor blocker therapies, François played an integral part in the company’s recent acquisition by Novo Nordisk, totaling up to US$1.075 billion, following an aggregated capital raising of US$110M in three financing rounds over only four years. 

François has contributed to the biotech and pharmaceutical industry for more than 20 years, a period during which he built a comprehensive set of skills in pharmaceutical and business development, as well as a proven ability to identify strategic assets, assemble and lead teams of experienced drug developers to move products forward to address unmet medical needs. 

Prior to Inversago, François focused on drug development in increasing leadership roles, from early-stage development programs to clinical trials, with key contribution to one approved NDA. François holds a PhD in physical chemistry from McGill University.